Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Plasma cell 1Myeloid 1Gynecologic 1Breast 1

Conditions

Stomach Neoplasms 75Colorectal Neoplasms 28Breast Neoplasms 23Esophageal Neoplasms 20Pancreatic Neoplasms 13Carcinoma, Non-Small-Cell Lung 11Colonic Neoplasms 10Rectal Neoplasms 9Ovarian Neoplasms 8Endometrial Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Gallbladder Neoplasms 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Uterine Cervical Neoplasms 5Prostatic Neoplasms 5Lung Neoplasms 5HER2-positive Gastric Cancer 5Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Adenocarcinoma 4Thyroid Neoplasms 3Salivary Gland Neoplasms 3Bile Duct Neoplasms 3Vulvar Neoplasms 2

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 45pembrolizumab 35Fluorouracil 32Capecitabine 31lenvatinib 26durvalumab 26Leucovorin 26Magnetic Resonance Spectroscopy 14Irinotecan 13Drug Therapy 13Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12Specimen Handling 11Radiofrequency Ablation 11130-nm albumin-bound paclitaxel 11tislelizumab 10pemigatinib 10apatinib 10Taxes 10Radiotherapy 10Floxuridine 10Folfox protocol 9Bevacizumab 9S 1 (combination) 8Photochemotherapy 8Liver Transplantation 8Cholangiopancreatography, Endoscopic Retrograde 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Trastuzumab × Gastrointestinal × Clear all
NCT06178445 2026-03-27

TRAP-BTC

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
24 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03613168 2021-01-05

BILHER

Asan Medical Center

Phase 2 Completed
4 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡